Contemporary Clinical Trials当代临床试验
Contemporary Clinical Trials(英文缩写 CONTEMP CLIN TRIALS),ISSN 1551-7144,eISSN 1559-2030,中文译名:当代临床试验 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-10-01 至 2026-09-30，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.261 | Q4 |
| 2022 | 2.200 | Q4 |
| 2023 | 2.000 | Q3 |
| 2024 | 1.900 | Q3 |
| 2025 | 1.900 | Q3 |
Contemporary Clinical Trials 最新收录文献
-
1. Land- and water-based supervised exercise intervention for women with fibromyalgia: a CERT-based protocol from the al-Ándalus randomized controlled trial.
PMID:日期:2026-10-04Exercise is a core non-pharmacological treatment for fibromyalgia and is consistently recommended in clinical guidelines. However, exercise interventions are often inadequately reported, limiting reproducibility, implementation in clinical practice, and comparison across studies. This article aims to provide a comprehensive description of the rationale, design, and delivery of the land- and water-based exercise interventions implemented in the al-Ándalus Randomized Controlled Trial (RCT), following the Consensus on Exercise Reporting Template (CERT). Women aged 35-65 years diagnosed with fibromyalgia (n = 180) were recruited in Southern Spain (Andalucía) and allocated to one of three groups: usual care (control), land-based supervised exercise, or water-based supervised exercise (n = 60 per group). Participants in the intervention groups completed a 24-week supervised multicomponent exercise program comprising aerobic, strength, and flexibility training delivered three times per week on non-consecutive days (45-60 min/session). The intervention rationale, progression criteria, supervision procedures, adherence strategies, and exercise components are reported according to the 16-item CERT checklist. This report provides a detailed and standardised description of a supervised multicomponent exercise intervention for women with fibromyalgia delivered in both land- and water-based settings. By facilitating transparency, reproducibility, and implementation, the protocol may serve as a practical resource for clinicians and exercise professionals and as a methodological reference for researchers seeking to improve the reporting quality of exercise interventions in fibromyalgia and other chronic musculoskeletal conditions. ClinicalTrials.gov ID: NCT01490281.
-
2. Contingency management plus deep transcranial magnetic stimulation for the treatment of cocaine use disorder: Protocol of a randomized controlled trial.
PMID:日期:2026-10-03Contingency Management (CM) is the most effective behavioral treatment for cocaine use disorder (CUD), with early response strongly predicting sustained abstinence. However, a substantial subset of individuals fail to respond. A logical next step is to augment CM with an intervention that targets relevant neural circuits. Using a staged design, this study will test whether adding deep transcranial magnetic stimulation (TMS) to lateral prefrontal and insular regions improves outcomes among CM non-responders. This randomized, double-blind, sham-controlled trial will enroll 100 treatment-seeking adults with CUD. During Stage 1 (Weeks 1-2), all participants will receive high-magnitude CM. Initial response is defined as achieving two consecutive weeks of cocaine-negative urine samples. During Stage 2 (Weeks 3-10), participants who do not achieve abstinence will be classified as non-responders and randomized to active or sham deep TMS in addition to continued CM. The accelerated TMS protocol will include three sessions of intermittent theta burst stimulation delivered three times weekly for six weeks, followed by weekly sessions for two weeks. Primary analyses will evaluate the effects of CM + TMS on cocaine abstinence, reduced use, and craving among CM non-responders. Secondary analyses will examine mechanistic targets, including changes in anterior insular-amygdala connectivity and NIDA Phenotyping Assessment Battery domains of cognition, reward, and negative emotionality. Analyses will use intention-to-treat generalized linear modeling under both frequentist and Bayesian frameworks. This trial may advance mechanistic insights and inform clinical strategies to improve outcomes for individuals with resistant CUD. gov Identifier NCT07490600.
-
3. Optimal rule-based general A+B designs in phase I clinical trials.
PMID:日期:2026-10-02Lin et al. studied the statistical properties of rule-based general A+B designs using true toxicity probabilities, without and with dose de-escalation, and derived exact formulae for key statistical quantities essential for phase I clinical trials. We systematically evaluate the impact of the parameters of A, B, C, D and E on the key statistical quantities across five dose levels within the A+B=6 framework. Simulation studies are conducted with true toxicity probabilities generated using a dose-toxicity model on known prior toxicity probabilities. General A+B designs with dose de-escalation are more conservative than those without dose de-escalation. For either presence or absence of dose de-escalation, 1) under an under-toxic environment, the 33,222 design is the best design and 24,113 design is the second one, but 33,222 design requires two more patients expected to be treated than 24,113 design. 2) under a moderate-toxic and over-toxic environment, 24113 and 42,111 design demonstrates an absolute and evident superiority, respectively. 3) under an unknown-toxic environment, 33122 design is the optimal choice but requires a larger total number of patients expected to be treated. 4) under an over-/unknown-toxic environment, the traditional "3+3" is one of the top two smallest total number of patients expected to be treated and patients experiencing a dose-limiting toxicity. Some general A+B designs have superior performance than traditional "3+3" design, having the target toxicity level closest to target toxicity rate (TTR) and higher number of patients treated at the dose levels with toxicity probabilities close to TTR.
-
4. Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
PMID:日期:2026-10-01Survodutide (BI 456906) is an investigational once-weekly dual glucagon and Glucagon-like Peptide (GLP-1) receptor agonist being developed for obesity. In a phase 2 trial involving adults with a body mass index ≥27 kg/m without diabetes, participants assigned to the 4.8-mg dose achieved a mean body-weight reduction of up to 18.7% at 46 weeks, compared with 2.3% with placebo. Its proposed mechanism combines reduced food intake through GLP-1 receptor agonism with glucagon receptor-mediated effects on energy expenditure and hepatic metabolism. Gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were common and were influenced by dose escalation. Phase 3 SYNCHRONIZE trials are evaluating efficacy, safety, and tolerability in broader populations with and without type 2 diabetes. Survodutide is not approved for routine clinical use, and its comparative effectiveness, durability, long-term safety, treatment persistence, and effects after discontinuation remain to be established.
-
5. Tailoring physical activity maintenance strategies for cancer survivors: A study protocol for an adaptive intervention.
PMID:日期:2026-09-27Moderate-vigorous physical activity (MVPA) (i.e., aerobic and resistance exercise) is effective for improving multiple health outcomes for cancer survivors, and structured, supervised community-based exercise programs can facilitate MVPA adoption among cancer survivors. However, maintaining MVPA after these programs end can be challenging for some. The purpose of this paper is to describe the protocol of an adaptive intervention designed to enhance MVPA maintenance among cancer survivors who have recently completed a community-based exercise program. Participants are insufficiently active cancer survivors who are ≤5 years of completing cancer treatment(s) and are enrolled or planning to enroll in one of three community-based exercise programs. Three months after completion of the program, MVPA will be measured and participants will be randomized to a 3-month, adaptive maintenance intervention based on their MVPA response (i.e., achieving exercise guidelines for cancer survivors). Outcomes are feasibility and acceptability of the maintenance intervention, and MVPA six months following completion of the initial exercise program. Outcomes will be assessed using quantitative surveys, focus groups, and objective and self-reported MVPA. This study is expected to demonstrate the feasibility and acceptability of an adaptive intervention to enhance MVPA maintenance for cancer survivors following community-based exercise programs. Findings may identify optimal strategies for sustaining MVPA long-term, and inform the development of scalable, evidence-based stepped care approaches that can be integrated into community-based exercise programs.
-
6. Dietary intake, sleep assessment, and chronotype in time-restricted eating feasibility protocols.
PMID:日期:2026-09-27该文献暂无摘要。
-
7. The effect of surgical prehabilitation on autonomic nervous system regulation: Rationale and design of the TUNE trial.
PMID:日期:2026-09-27Prehabilitation improves physiological readiness for major surgery; however, its implementation and evaluation remain inconsistent, particularly in thoracic surgery. Current assessments largely rely on functional tests, which are difficult to standardize and provide limited knowledge of biological resilience. Heart-rate variability (HRV) is an objective marker of autonomic nervous system balance and is already widely used in sports medicine to guide training intensity and evaluate the relationship between physiological stress and recovery. Given its ability to capture the dynamicity and flexibility of autonomic regulation, HRV may become a practical tool to assess the physiological effects of prehabilitation interventions, going beyond traditional endpoints. The TUNE trial is a multicenter, open label, randomized controlled trial involving patients scheduled for elective major thoracic surgery. Participants are randomized in a 1:1 ratio to receive either a home-based multimodal prehabilitation program in addition to standard care or standard care alone. The intervention consists of a 4 week remotely delivered program including structured physical exercise, personalized nutritional optimization and psychological support. The trial is ongoing and currently recruiting participants. The primary endpoint is the between-group difference in the change of HRV, measured as the standard deviation of normal-to-normal intervals (SDNN), from baseline to preoperative assessment. Secondary outcomes include correlations between HRV and clinical outcomes. The TUNE trial will provide data to assess whether a prehabilitation program can improve HRV and facilitate recovery in patients undergoing major thoracic surgery. This trial was registered on ClinicalTrials.gov with the trial identification NCT06398301.
-
8. Befriending with GENIE (BwGEN): a pragmatic randomised controlled trial protocol to reduce loneliness and increase social support among migrants living with dementia.
PMID:日期:2026-09-25Culturally and linguistically diverse (CaLD) Australians living with dementia and their families experience high rates of loneliness and social isolation and struggle to access culturally relevant services. This protocol describes an Australian trial assessing the impact of Befriending with GENIE (BwGEN), an intervention aimed at reducing loneliness and increasing social connection, service knowledge and access among culturally and linguistically diverse older adults living with mild to moderate dementia and their families. BwGEN is a novel, co-designed intervention that combines a befriending program with GENIE, a networking intervention comprising a web-based software tool and network mapping activities that facilitate participants' awareness about their social network, support needs, and knowledge of services. The intervention consists of eight weekly one-hour BwGEN visits, delivered by a trained bilingual facilitator. In this pragmatic randomised controlled trial (RCT) 60 dyads (people with dementia and their family carer) in the intervention group receive BwGEN and 60 dyads in the control group receive usual care. Participants will be recruited through partner organisations and culturally tailored outreach activities across four states in Australia. People with dementia must be aged 65+ and be from one of four language and cultural groups: Chinese, Italian, South Asian, and Vietnamese. Outcome measures will be collected by blinded, bilingual outcome assessors at four timepoints: baseline, week 4, week 8 and week 16 (follow-up). The primary outcome is loneliness in the participant with dementia, and secondary outcomes include quality of life and social wellbeing of participant dyads, social support network for participant with dementia, and carer loneliness and burden. A health economic evaluation, process evaluation and qualitative study are conducted within the trial. This is the first RCT evaluating BwGEN. If the intervention proves effective it may be incorporated into community and home-based service provider programs servicing CaLD clients. anzctr.org.au; ACTRN12623001286639. Prospectively registered on 11/12/2023.
-
9. Impact of aquatic versus land exercise on glycated hemoglobin and blood pressure in older adults with multimorbidity: A randomized controlled trial protocol.
9. 水上运动与陆地运动对患有多种慢性病老年人糖化血红蛋白和血压的影响：一项随机对照试验方案PMID:日期:2026-09-23Multimorbidity is defined as the prese of two or more chronic conditions in the same individual, being a growing global health concern, particularly among older adults. This condition is associated with decreased quality of life, increased healthcare utilization, and functional decline. Although physical exercise is widely recommended for managing chronic diseases, such as hypertension and type 2 diabetes, evidence remains limited regarding the most effective exercise modality for individuals with multimorbidity. This study protocol outlines a randomized controlled trial designed to compare the effects of water-based and land-based exercise programs on glycated hemoglobin and blood pressure in older adults with multiple chronic conditions. This protocol describes a single center, randomized controlled trial with stratified allocation based on comorbidity burden. A minimum of 42 participants aged 60 years or older, diagnosed with hypertension and type 2 diabetes mellitus plus other chronic conditions (i.e. obesity, dyslipidemias, depression/anxiety or osteoarthritic) will be recruited. Participants will be randomly assigned to a water exercise, land exercise, or a control group. The intervention groups will engage in supervised exercise sessions three times per week for 10 weeks, combining aerobic and resistance training. Primary outcomes include glycated hemoglobin and systolic blood pressure, whereas secondary outcomes include heart rate variability, lipid profile, spirometry, physical function, anthropometry, and patient-reported outcomes on quality of life, physical activity, sleep quality, and psychological health. Assessments will be conducted before and after the intervention following standardized procedures. This study is registered at ClinicalTrials.gov (NCT06879639).
-
10. How to PERSEVERE: Study protocol for a national, virtual, randomized controlled trial of a peer mentor-supported educational intervention for family caregivers of people with Lewy body dementia.
PMID:日期:2026-09-23Family caregivers of people living with Lewy body dementia (PLBD) experience significant strain and adverse health outcomes that consequently affect the health of their loved ones with Lewy Body Dementia (LBD). Effective LBD caregiver interventions are needed. Building on pilot work, our objective is to test the effects of PERSEVERE (Peer Mentor Support and Caregiver Education)- a 12-week peer mentor-supported, LBD-specific educational intervention -on caregiver knowledge, attitudes, strain, and PLBD quality of life and healthcare utilization in a national, virtual, randomized controlled trial. Partnering with LBD caregiver advisors and advocacy organizations, we are recruiting and enrolling 180 seasoned caregivers (having cared for a PLBD with ≥3 years of cognitive symptoms) and 502 novice LBD family caregivers (<3 years of cognitive symptoms). Seasoned caregivers train as Mentors. Novice caregivers are randomized 1:1 in cohorts of 100 to (1) the Mentee group receiving weekly Mentor calls covering a novel LBD curriculum focused on symptom management, future planning, and caregiver support, or (2) the attention-control group receiving pre-existing resources for self-directed learning. Primary outcomes include change from baseline in caregiver knowledge and attitudes at 12 weeks (post-intervention) and caregiver strain at nine months (follow-up). Secondary outcomes include engagement with materials and/or mentor, satisfaction, future interest, and change in PLBD quality of life and PLBD healthcare utilization at nine months. A peer mentor-delivered LBD-focused curriculum may improve caregiver and PLBD outcomes in a cost-effective, scalable manner. PERSEVERE has experienced robust national enrollment and retention within the first 18 months of recruitment, with outcomes forthcoming. Trial Registration https://clinicaltrials.gov/study/NCT06389032, registered on April 24, 2024.